565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer

Autor:	Pavani Chalasani, Joanne E. Mortimer, J. Alidzanovic, Rachel M. Layman, M. Suster, Julie R. Nangia, Hannah M. Linden, Y. Karchmit, M. Ptaszynski, Vandana G. Abramson, Z.J. Vranjes, J. Trifunovic, J. Suarez, Z. Andric, M. Milovic-Kovacevic, K. Crew
Rok vydání:	2021
Předmět:	Phase i ii Breast cancer Oncology business.industry Cancer research Dose escalation Estrogen receptor Medicine In patient Hematology Palbociclib business medicine.disease
Zdroj:	Annals of Oncology. 32:S619
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2021.08.1087
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f01a7d009e2525479e4bc2a3ca2941f7 https://doi.org/10.1016/j.annonc.2021.08.1087 Zobrazit plný text záznamu